Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
718 (USA) · Dr. Nolan
consented 2013-05-19
AEs
3
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Mild DIARRHOEA — outcome: RECOVERED/RESOLVED; onset 2013-11-16 (study day 182.0); relationship: NONE
moderate
assessed
Moderate SOMNOLENCE — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-06-03 (study day 16.0); relationship: POSSIBLE
moderate
assessed
Moderate SOMNOLENCE — outcome: RECOVERED/RESOLVED; onset 2013-06-03 (study day 16.0); relationship: POSSIBLE
Data queries
No data queries.